EFFICIENCY OF OVARIAN PROTECTION DURING CHEMOTHERAPY IN WOMEN WITH HODGKIN'S LYMPHOMA
- Authors: PYLOVA I.V1, SHMAKOV R.G2, DEMINA E.A1, LYUBIMOVA N.V1, SMETNIK V.P2, SAMOILOVA T.E3, MAKHOVA E.E1
-
Affiliations:
- N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences
- Academician V. I. Kulakov Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health and Social Development of the Russian Federation
- ZAO «MD PROJECT 2000» (Perinatal Medical Center), Moscow
- Issue: No 7-1 (2011)
- Pages: 40-45
- Section: Articles
- URL: https://journals.eco-vector.com/0300-9092/article/view/246610
- ID: 246610
Cite item
Open Access
Access granted
Abstract
Objective. To reveal the major risk factors of ovarian follicular depletion in women with Hodgkin’s lymphoma (HL) before antitumor therapy and to evaluate the efficiency of ovarian protection with combined oral contraceptives (COC) and gonadotropin-releasing hormone (GnRH) agonists. Subjects and methods. In 236 reproductive-age women with HL, ovarian function was evaluated by anamnestic, hormonal, and ultrasound studies prior to polychemotherapy (PCT) and 4-6 months after its termination. For ovarian protection, 52 and 24 women took COC and the GnRH agonist zoladex, respectively. Results. The preservation of a menstrual cycle after PCT depended on women’s age (p=0.000001), the symptoms of intoxication (p=0.04), the stage of disease (p=0.00004), a patient’s general condition (p=0.002), the presence of anemia (p=0.04) and albuminemia (p=0.008), and radiation of inguinal and iliac lymph nodes (p=0.003). Hypoestrogenia and decreased inhibin levels were found to be of prognostic value for the development of postchemotherapeutic amenorrhea; threshold values were determined for these hormones. In the group of women receiving high-dose cyclophosphan therapy, hormonal ovarian protection reduced the rate of amenorrhea by 2.5-fold (p=0.007). The rate of preservation of normal menstrual function was statistically higher in the group of women taking a GnRH analogue (р<0.001).
Full Text
About the authors
I. V PYLOVA
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences
R. G SHMAKOV
Academician V. I. Kulakov Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health and Social Development of the Russian Federation
Email: mdshmakov@km.ru
E. A DEMINA
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences
N. V LYUBIMOVA
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences
V. P SMETNIK
Academician V. I. Kulakov Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health and Social Development of the Russian Federation
T. E SAMOILOVA
ZAO «MD PROJECT 2000» (Perinatal Medical Center), Moscow
E. E MAKHOVA
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences
References
- Демина Е.А. Лимфома Ходжкина. - М.: РЛС, 2004. - С. 605-614.
- Демина Е.А., Перилова Е.Е., Шмаков Р.Г. Использование комбинированных пероральных контрацептивов для профилактики повреждения функции яичников у больных лимфомой Ходжкина. - М.: РЛС, 2004. - С. 1352—1354.
- Демина Е.А., Махова Е.Е., Сусулева Н.А., Ильященко В.А. Возможности сохранения детородной функции у женщин с лимфомой Ходжкина // Рос.мед.журн. - 2005. - № 1. - С. 26—28.
- Шмаков Р.Г. Репродуктивное здоровье женщин с онкогематологическими заболеваниями: Автореф. дис.. д-ра. мед. наук. - М., 2008.
- Behringer K., Breuer K., Reineke T. et al. Secondary amenorrhea after Hodgkin lymphoma is influenced by age at treatment, stage of disease, chemotherapy regime and the use of oral contraceptives during therapy: a repot from the German Hodgkin Lymphoma Study Group // J. Clin. Oncol. -2005. - Vol. 23, № 30. - P. 7555—7564.
- Blumenfeld Z. Preservation of fertility and ovarian function and minimalization of chemotherapy associated gonadotoxicity and premature ovarian failure: the role of inhibin-A and -B as markers // Mol. Cell. Endocrinol. - 2002. - Vol. 187, № 1—2. - Р. 93—105.
- Blumenfeld Z., Wolff M. GnRH-analogues and oral contraceptives for fertility preservation in women during chemotherapy // Hum. Reprod. Update. - 2008. - Vol. 14, № 6. - Р. 543—552.
- Principles and practice of oncology/Eds V.T. De Vita et al. -6th ed. - Philadelphia: Lippincott Williams & Wilkins, 2001.
- Diehl V.J. Advanced Hodgkin’s disease: ABVD is better, yet is not good enough! // J. Clin. Oncol. - 2003. - Vol. 21, № 4. -P. 583—585.
- Franchi-Rezgul P., Rousselot P., Espie M. et al. Fertility in young women after chemotherapy with alkylating agents for Hodgkin and non-Hodgkin lymphomas // Hematol. J. - 2003. -Vol. 4, № 2. - Р. 116—120.
- Hodgkin lymphoma // Eds. R.T.Hoppe et al. - 2nd ed. -Philadelphia: Lippincott Williams & Wilkins, 2007.
- Lutchman Singh K., Davies M., Chatterjee R. Fertility in female cancer survivors: pathophysiology, preservation and the role of ovarian reserve testing // Hum. Reprod. Update. - 2005. -Vol. 11, № 1. - P. 69—89.
- Mattle V., Behringer K., Engert A., Wildt L. Female fertility after cytotoxic therapy - protection of ovarian function during chemotherapy of malignant and non-malignant diseases // Eur. J. Haematol. - 2005. - Vol. 66 (suppl.) - Р. 77—82.
Supplementary files
